Italian Lung Cancer Observational Study

NCT ID: NCT05851755

Last Updated: 2023-05-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

LUCENT is an observational study focused on malignant pulmonary and tracheo-bronchial disease. It involves a large proportion of reference Italian thoracic surgery centers. The relevance of the study is related to the epidemiology of lung cancer in the world - also known as "Big Killer" - and the high mortality rates both in males and females.

The aim of his prospective study is to collect a large bulk of postoperative patients' outcome data and to produce up-to-date descriptive statistics of patients undergoing surgery for lung cancer. These results will be pivotal to compare the clinical results of all the relevant specialities involved in the care of lung cancer such as medical oncologists and radiation oncologists.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with lung cancer
* informed consent

Exclusion Criteria

* alcohol or drug abuse
* age \< 18
* inability to express consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

S. Andrea Hospital

OTHER

Sponsor Role collaborator

Azienda Policlinico Umberto I

OTHER

Sponsor Role collaborator

Azienda Ospedaliero, Universitaria Pisana

OTHER

Sponsor Role collaborator

Università degli Studi dell'Aquila

OTHER

Sponsor Role collaborator

University of Milan

OTHER

Sponsor Role collaborator

Azienda Ospedaliera di Perugia

OTHER

Sponsor Role collaborator

Monaldi Hospital

OTHER

Sponsor Role collaborator

Azienda Ospedaliera di Bolzano

OTHER

Sponsor Role collaborator

AUSL Romagna Rimini

OTHER

Sponsor Role collaborator

European Institute of Oncology

OTHER

Sponsor Role collaborator

Università degli Studi di Ferrara

OTHER

Sponsor Role collaborator

Azienda Socio Sanitaria Territoriale di Mantova

OTHER

Sponsor Role collaborator

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roberto Crisci, MD

Role: PRINCIPAL_INVESTIGATOR

University of Aquila

Luca Bertolaccini, MD

Role: PRINCIPAL_INVESTIGATOR

European Institute of Oncology

Alessandro Bertani, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS ISMETT -UPMC ITALY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of L'Aquila

L’Aquila, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Bertolaccini L, Ciani O, Lucchi M, Zaraca F, Bertani A, Crisci R, Spaggiari L; LUCENT Study Group. Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT). JMIR Res Protoc. 2024 Oct 8;13:e57183. doi: 10.2196/57183.

Reference Type DERIVED
PMID: 39378423 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRRB/04/23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tunisian Lung Cancer Study
NCT06934499 RECRUITING
Molecular Profiling Project
NCT04025515 RECRUITING